TradeOrgs
  • 🇮🇳 India
  • 🇺🇸 US
  • Screener
  • Backtest
  • Watchlist
  • Signals
  • Portfolio
  • Insights
  • Connect
Sign in
RELIANCE₹1,377.50▲ 14.60%TCS₹2,376.20▼ 3.44%HDFCBANK₹846.00▲ 18.82%ICICIBANK₹1,640.00▲ 18.75%INFY₹1,098.00▼ 2.89%HINDUNILVR₹2,052.50▲ 10.75%ITC₹299.10▲ 14.69%SBIN₹1,165.10▲ 19.66%BHARTIARTL₹2,161.70▲ 15.28%KOTAKBANK₹515.80▲ 16.62%LT₹4,209.10▲ 14.94%AXISBANK₹1,446.00▲ 16.99%ASIANPAINT₹2,608.30▲ 11.91%MARUTI₹14,011.00▲ 22.10%AAPL$342.56▲ 0.90%MSFT$484.52▼ 8.90%GOOGL$265.29▼ 22.04%AMZN$246.82▼ 6.02%NVDA$125.53▼ 42.01%META$560.84▼ 19.22%TSLA$345.82▼ 7.46%BRK-B$570.00▲ 5.59%JPM$310.53▼ 7.38%V$401.87▼ 1.16%
RELIANCE₹1,377.50▲ 14.60%TCS₹2,376.20▼ 3.44%HDFCBANK₹846.00▲ 18.82%ICICIBANK₹1,640.00▲ 18.75%INFY₹1,098.00▼ 2.89%HINDUNILVR₹2,052.50▲ 10.75%ITC₹299.10▲ 14.69%SBIN₹1,165.10▲ 19.66%BHARTIARTL₹2,161.70▲ 15.28%KOTAKBANK₹515.80▲ 16.62%LT₹4,209.10▲ 14.94%AXISBANK₹1,446.00▲ 16.99%ASIANPAINT₹2,608.30▲ 11.91%MARUTI₹14,011.00▲ 22.10%AAPL$342.56▲ 0.90%MSFT$484.52▼ 8.90%GOOGL$265.29▼ 22.04%AMZN$246.82▼ 6.02%NVDA$125.53▼ 42.01%META$560.84▼ 19.22%TSLA$345.82▼ 7.46%BRK-B$570.00▲ 5.59%JPM$310.53▼ 7.38%V$401.87▼ 1.16%

TradeOrgs shows market information and analyzes your own trading history. It does not place trades and is not investment advice.

Prices and listings are for information only. We are read-only against your broker account.

Technical signals (RSI, MACD, etc.) are educational readouts of public indicators — not recommendations.

Privacy Policy·© 2026 TradeOrgs

← US stocks

🇺🇸ABCL

AbCellera Biologics Inc. - Common Shares

NASDAQ
$9.69
▼ $2.02 (-17.3%)
Live· just now
delayed feed · not for order timing

Price history · 20-day (cyan) / 50-day (purple) avg

as of 20 Nov 2026
H $15.02L $3.94+136.9%
$15.02$12.8$10.59$8.37$6.16$3.94$9.69
RSI (14)
Intraday · 15-minSell-15RSI 34DowntrendMACD Bullishfor day-trading context — not advice

Technical signal

Sell-20
RSI (14)34
oversold 30overbought 70
Trend
Downtrend
MACD
Bearish
Bollinger
Below lower band
vs 20-day
below
vs 50-day
below
vs 200-day
above
Support
$9.58
Resistance
$13.86
  • Price is below its 50-day average (medium-term weakness).
  • Price is above its 200-day average (long-term uptrend).

Signal backtest · 2026-02-20 → 2026-11-20

Strategy return
+164.7%
Buy & hold
+218.7%
Trades
6
Win rate
33%

$100,000.00 invested would be worth $264,736.87 (+164.7%) · Full backtester →

Hypothetical: go long when the signal turns Buy, exit when it turns Sell. Past indicator behavior is not a prediction — educational only, not advice.

About AbCellera Biologics Inc.· Biotechnology

source: yahoo

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Sector
Healthcare
Industry
Biotechnology
Employees
562
Headquarters
Vancouver, Canada
www.abcellera.com ↗

Fundamentals

No fundamental data is currently available for this listing from our data providers.

Recent news

News sentiment:— Neutral0↑ · 0↓ · 8–
  • Insulet downgraded, Tandem Diabetes upgraded: Wall Street's top analyst calls— Neutral
    The Fly · 18 Nov 2026
  • AbCellera Biologics Targets 2027 Late-Stage Trial for Hot Flash Treatment— Neutral
    MarketBeat · 16 Nov 2026
  • Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year?— Neutral
    Zacks · 12 Nov 2026
  • AbCellera Biologics Eyes Phase 3 for Hot-Flash Drug After Promising Midstage Results
  • Price is below the lower Bollinger Band (stretched to the downside).
  • Educational technical indicators — not investment advice. TradeOrgs does not place trades.

    — Neutral
    MarketBeat · 12 Nov 2026
  • AbCellera Biologics Inc (ABCL) (Q3 2026) Earnings Call Highlights: Breakthrough Hot Flash Data ...— Neutral
    GuruFocus.com · 10 Nov 2026
  • AbCellera (ABCL) Q3 2026 Earnings Call Transcript— Neutral
    Motley Fool · 10 Nov 2026
  • Sentiment is a keyword-based read of the headline — a rough signal, not advice.